
Inhibrx Biosciences, Inc. (NASDAQ:INBX – Free Report) – Analysts at HC Wainwright decreased their FY2026 EPS estimates for shares of Inhibrx Biosciences in a research note issued to investors on Monday, November 16th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($9.22) for the year, down from their prior forecast of ($8.93). HC Wainwright has a “Buy” rating and a $220.00 price target on the stock. The consensus estimate for Inhibrx Biosciences’ current full-year earnings is ($9.70) per share. HC Wainwright also issued estimates for Inhibrx Biosciences’ Q4 2026 earnings at ($2.27) EPS, Q1 2027 earnings at ($2.23) EPS, Q2 2027 earnings at ($2.18) EPS, Q3 2027 earnings at ($1.94) EPS, Q4 2027 earnings at ($1.72) EPS and FY2027 earnings at ($8.02) EPS.
Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($2.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.45) by ($0.01). The business had revenue of $2.00 million for the quarter, compared to analyst estimates of $1.90 million.
Read Our Latest Stock Report on Inhibrx Biosciences
Inhibrx Biosciences Stock Up 7.6%
Shares of NASDAQ INBX opened at $74.33 on Wednesday. The company has a 50 day simple moving average of $91.98 and a two-hundred day simple moving average of $92.09. Inhibrx Biosciences has a fifty-two week low of $57.30 and a fifty-two week high of $155.29.
Insider Buying and Selling at Inhibrx Biosciences
In other news, Director Jon Kayyem acquired 5,000 shares of Inhibrx Biosciences stock in a transaction on Wednesday, September 23rd. The stock was acquired at an average cost of $100.00 per share, for a total transaction of $500,000.00. Following the purchase, the director owned 434,360 shares in the company, valued at $43,436,000. This trade represents a 1.16% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Mark Lappe bought 10,040 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was purchased at an average cost of $84.56 per share, with a total value of $848,982.40. Following the completion of the acquisition, the chief executive officer directly owned 745,588 shares of the company’s stock, valued at approximately $63,046,921.28. The trade was a 1.36% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 62,540 shares of company stock worth $6,347,507 and sold 1,500 shares worth $168,590. 18.26% of the stock is owned by company insiders.
Institutional Investors Weigh In On Inhibrx Biosciences
Several institutional investors and hedge funds have recently made changes to their positions in the company. Sterling Capital Management LLC boosted its position in shares of Inhibrx Biosciences by 380.3% during the third quarter. Sterling Capital Management LLC now owns 293 shares of the company’s stock valued at $29,000 after buying an additional 232 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in Inhibrx Biosciences in the 2nd quarter worth about $31,000. China Universal Asset Management Co. Ltd. increased its holdings in Inhibrx Biosciences by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,685 shares of the company’s stock worth $281,000 after buying an additional 350 shares in the last quarter. Quantbot Technologies LP purchased a new position in Inhibrx Biosciences in the 2nd quarter worth about $68,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Inhibrx Biosciences in the 3rd quarter worth about $75,000. Institutional investors own 82.46% of the company’s stock.
Inhibrx Biosciences News Summary
Investors following INBX have been watching these news items:
- Positive Sentiment: Ozekibart combination treatment produced a reported 62.7% response rate in Ewing sarcoma. This promising clinical result could strengthen the drug’s potential and is the clearest positive news for INBX. Article: Inhibrx Reports 62.7% Response Rate For Ozekibart Combination In Rare Cancer Ewing Sarcoma
- Neutral Sentiment: HC Wainwright maintained its Buy rating and $220 price target. Its estimates were mixed: it raised its FY2027 EPS forecast to a smaller loss of $8.02, but lowered its FY2026 estimate to a larger loss of $9.22. These are forecasts, not a change in the company’s reported results.
- Negative Sentiment: HC Wainwright cut its price target, which could weigh on sentiment despite the retained Buy rating. The available report summary does not specify the previous target. Article: Inhibrx Biosciences Stock Price Target Cut by HC Wainwright
About Inhibrx Biosciences
Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.
Featured Articles
- Five stocks we like better than Inhibrx Biosciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
